Non-Invasive Assessment of Liver Fibrosis and Steatosis in End-Stage Renal Disease Patients Undergoing Renal Transplant Evaluation

Taseen Syeda, b, e, Nikita Chadha c, Dhiren Kumar b, d, Gaurav Gupta b, d, Richard K. Sterling a, b, c

Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) has an increased prevalence in end-stage renal disease (ESRD) due to similar risk factors. The aim of this study was to assess non-invasive testing including transient elastography (TE) for liver stiffness (LS), controlled attenuated parameter (CAP) for steatosis, Fibrosis-4 (FIB-4) score, aspartate aminotransferase (AST) to platelet ratio index (APRI) and NAFLD fibrosis score (NFS), for evaluation of NAFLD along with advanced fibrosis (AF) in patients with ESRD undergoing renal transplant evaluation.

Methods: Data were retrospectively collected within 12 weeks of TE. Primary outcomes were AF, defined by LS ≥ 9 kPa compared to APRI > 1.5, FIB-4 > 2.67, and NFS of 0.675, and ≥ 5% steatosis by CAP ≥ 263 dB/m compared to liver histology when available.

Results: A total of 171 patients were evaluated: mean age 56, 65% male, 36% obese, 47% had diabetes, 96% hypertension, and 56% dyslipidemia. Mean LS was 6.5 kPa with 21% having AF. Mean CAP was 232 dB/m, with 25% having steatosis. Those with AF were older with higher NFS. Those with steatosis were obese and had diabetes without higher LS or fibrosis scores. Only NFS was associated with LS ≥ 9 kPa. In those with liver histology, AF was associated with LS ≥ 9 kPa but not with APRI, FIB-4, or NFS.

Conclusions: Despite normal liver enzymes, non-invasive assessment via TE in ESRD patients exhibited high prevalence of AF and steatosis not detected by APRI or FIB-4 scores. This high prevalence was secondary to the common risk factors such as obesity and diabetes, among patients with NAFLD and ESRD.

Keywords: Non-invasive fibrosis assessment; Fibrosis-4 score; Fibroscan; Transient elastography; APRI; NFS

Introduction

Among all chronic liver disease etiologies, non-alcoholic fatty liver disease (NAFLD) has the potential to be the leading cause of end-stage liver disease and as such has major transplant implications [1]. Non-alcoholic steatohepatitis (NASH) cirrhosis is the fastest growing etiology of liver failure requiring liver transplant [1-3]. NAFLD has been linked to the development and progression of chronic kidney disease (CKD) and often coexist [4, 5]. This is attributed to the common metabolic syndrome (MS) risk factors for NAFLD and CKD including obesity (body mass index (BMI) ≥ 30 kg/m²), diabetes mellitus (DM), hypertension (HTN) and dyslipidemia (DL) [6-9]. Therefore, hepatic fibrosis may also be highly prevalent in patients with end-stage renal disease (ESRD) on dialysis [10]. Because many with ESRD have normal liver enzymes (alanine aminotransferase (ALT) and aspartate aminotransferase (AST)), few undergo liver biopsy [11]. For assessment of hepatic fibrosis, non-invasive testing has mostly replaced liver biopsy. However, the use of these tests among those with concomitant NAFLD and ESRD is unknown.

Liver biopsy is considered to be the gold standard to establish the degree of fibrosis; but due to its invasive nature, it is associated with complications including bleeding, bile leaks, infection, pneumothorax, intestinal perforation and death [12]. The increased bleeding risk in those with ESRD may be due to poor platelet function [11, 13]. Because of these complications and the likelihood of sampling error, there has been interest in non-invasive tests to determine the degree of hepatic fibrosis and steatosis. Transient elastography (TE) and magnetic resonance elastography (MRE) to measure liver stiffness (LS) are two imaging modalities that can be used to detect hepatic fibrosis [14, 15]. Though TE is considered a
valuable tool in fibrosis assessment, its utility in ESRD patients on dialysis is limited due to chronic volume overload and sampling variability based on probe location [16-20]. Unlike imaging-based TE, serum-based non-invasive tests depend on laboratory parameters including ALT level that tends to be normal in patients with CKD and decrease further with worsening severity of disease [21]. Non-invasive serum-based tests including AST to platelet ratio index (APRI) and Fibrosis-4 (FIB-4) scores have shown variable diagnostic accuracy for advanced fibrosis dependent on ALT levels in patients with hepatitis C virus (HCV) infection and ESRD [22]. Furthermore, due to normal ALT levels the prevalence of NAFLD in ESRD is unknown and the impact of ALT normalization on non-invasive fibrosis assessment is unclear. To address this gap in knowledge, the aim of this study was to assess the degree of advanced fibrosis and steatosis in patients with ESRD by assessing LS and controlled attenuated parameter (CAP) via TE and to compare performance of TE with other serum-based non-invasive tests.

Materials and Methods

This was a retrospective cohort study designed to describe the presence of hepatic fibrosis and steatosis in patients who had ESRD. All patients were also being evaluated for renal transplant and had non-invasive testing as part of pre-transplant evaluation. Given the poor performance of serum-based tests in those with chronic HCV in those with ESRD [22], both serum- and imaging-based tests were used by our center. Non-invasive tests were identified using a PubMed Search and the selected models were free of additional cost and used routinely available laboratory data. The non-invasive tests included were APRI [23], FIB-4 score [24], and NAFLD fibrosis score (NFS) [25] in addition to TE [26]. The formulas for these models are included here (Supplementary Material 1, www.gastrores.org). These tests were performed on all patients irrespective of underlying etiology for ESRD within 12 weeks of TE. We excluded those individuals with underlying liver disease including hepatitis B, hepatitis C, autoimmune hepatitis, alpha-1-antitrypsin deficiency, Wilson disease, hemochromatosis, primary sclerosing cholangitis, primary biliary cholangitis and those with active alcohol intake to limit any confounders to non-invasive testing interpretation. Clinical data to define metabolic syndrome were collected at the time of TE. Presence of DM, HTN, and DL (increased triglycerides or total cholesterol) were defined by charted clinical diagnosis or use of appropriate treatment medications. Obesity was defined as BMI ≥ 30 kg/m².

The primary outcomes for this analysis were advanced fibrosis (stage ≥ 3) and steatosis (≥ 5%), defined as LS ≥ 9 kPa and CAP ≥ 263 dB/m, respectively on TE [27]. TE was performed after an overnight fast by trained personnel on a non-dialysis day. Unreliability of LS measurement was defined as interquartile range (IQR)/median > 30%, and technical failure was defined by the inability to obtain 10 valid measurements. Only cases with ≥ 10 valid acquisitions were used. Patients on peritoneal dialysis had all peritoneal fluid drained prior to measurements. TE was performed by experienced providers who performed more than 500 TE prior to the study. Demographic, clinical and laboratory data were collected within 12 weeks of TE. Subsequently, APRI, FIB-4, and NFS were calculated using basic metabolic panel, hepatic panel, complete blood count and international normalized ratio in addition to anthropometric data. Liver biopsy was performed in a subset of population as a required part of the renal transplant evaluation in those suspected of having advanced fibrosis regardless of ALT level or non-invasive test and the results ranged from no fibrosis (F0) to cirrhosis (F4) using Knodell score [28]. The decision to perform liver biopsy was made by the transplant nephrologist, if there was a discrepancy in non-invasive testing suggesting advanced fibrosis that might impact kidney transplant candidacy and not influenced by study inclusion criteria. Slides were stained with Masson’s trichrome and evaluated by a hepatopathologist. Advanced fibrosis was defined as either bridging fibrosis (F3) or cirrhosis (F4). The study was approved by the Virginia Commonwealth University Institutional Review Board, and was conducted in compliance with the ethical standards of the responsible institution on human subjects as well as with the Helsinki Declaration.

For categorical variables, data were recorded using frequency and percentage. Continuous variables were reported as mean ± standard deviation (SD) if normally distributed and median with IQR if skewed. Univariate and multivariate analysis were performed to identify factors associated with advanced fibrosis and steatosis. We used analysis of variance (ANOVA) and Student’s t-test to test for differences in normally distributed continuous variables, Mann-Whitney U test for non-normally distributed continuous variables, and Chi-square or Fisher’s exact test for categorical variables. Established cutoffs for advanced fibrosis (≥ F3) were used for each non-invasive test (APRI > 1.5, FIB-4 > 2.67, NFS > 0.675); and for TE, we used LS ≥ 9 kPa and CAP ≥ 263 dB/m [25, 27, 29-31]. In those with available liver histology, the utility of APRI, FIB-4, NFS and LS to predict advanced fibrosis was assessed. All statistics were performed using JMP Pro14 (SAS Institute). All authors had access to the study data and reviewed and approved the final manuscript.

Results

Patient cohort

A total of 171 patients were included in our analyses. General characteristics of the cohort are reported in Table 1. The average age was 56 ± 12 years and 65% were male. African Americans were the majority, making 60% of the population. Patients were overweight with BMI of 28.9 ± 5.4 kg/m² with 36% of the population obese with BMI ≥ 30 kg/m². None of the patients had underlying heart failure. XL probe was used in 38% of patients for TE. Metabolic syndrome comorbidities were common with HTN the most prevalent (96%) followed by DM (47%) and DL (56%). The median (IQR) of AST, ALT, and platelet count were 24 IU/L (19 - 35), 18 IU/L (13 - 29),
and 201 × 10³/mL (157 - 262), respectively.

Non-invasive assessment of fibrosis

Table 2 shows detailed assessment of individual non-invasive tests to identify advanced fibrosis (≥ F3) by TE. The median (IQR) of LS assessed by TE was 6.5 kPa (4.7 - 8.9) and 36 (21%) patients had advanced fibrosis (≥ F3). The mean APRI, FIB-4, and NFS were 0.35, 1.97, and -0.408, respectively. APRI, FIB-4 and NFS suggested advanced fibrosis (≥ F3) in three (1.8%), 26 (15%) and 39 (23%) patients, respectively. Table 3 compares those with and without advanced fibrosis by TE. Among all non-invasive tests only NFS showed reasonable accuracy to detect advanced fibrosis by TE. The odds ratio (OR) (95% confidence interval (CI)) of having LS ≥ 9

Table 1. Demographic and Clinical Values of the Study Population

| Characteristic          | Patient cohort (n = 171) |
|-------------------------|-------------------------|
| Agea                   | 56 (12)                 |
| Male, n (%)            | 111 (65)                |
| Black, n (%)           | 102 (60)                |
| Non-Hispanic           | 99%                     |
| BMI (SD)               | 28.9 (5.4)              |
| BMI ≥ 30, n (%)        | 61 (36)                 |
| Diabetes, n (%)        | 80 (47)                 |
| Hypertension, n (%)    | 164 (96)                |
| Dyslipidemia, n (%)    | 95 (56)                 |
| AST (IU/L)             | 31 (29)a, 24 (19 - 35)b |
| ALT (IU/L)             | 29 (45)a, 18 (13 - 29)b |
| Platelets (× 10³/mL)   | 215 (86)a, 201 (157 - 262)b |

| Variables and models | LS < 9 kPa | LS ≥ 9 kPa | P values |
|----------------------|------------|------------|----------|
| Patients (n)         | 135        | 36         |          |
| Male (%)             | 61         | 75         |          |
| Black (%)            | 59         | 64         |          |
| Agea                 | 54 (12)    | 62 (10)    | 0.005    |
| %BMI ≥ 30            | 37         | 31         |          |
| %DM                  | 44         | 56         |          |
| %CAP > 263 dB/m      | 25         | 25         |          |
| %DL                  | 54         | 62         |          |
| XL probe (%)         | 38         | 35         |          |
| %CAP > 263 dB/m      | 25         | 25         |          |
| %FIB-4 > 2.67        | 20         | 23         |          |
| %NFS > 0.675         | 16         | 36         | 0.007    |

| Non-invasive tests   | Established cutoffs | Results |
|----------------------|---------------------|---------|
| Transient elastography (TE) | LS (kPa) | 8.3 (7.1)a, 6.5 (4.7 - 8.9)b |
|                       | LS IQR/median^a     | 13.2 (5.4) |
|                       | LS ≥ 9              | 21%      |
|                       | CAP (dB/m)^a        | 232 (61) |
|                       | CAP IQR^a           | 40 (20)  |
|                       | CAP ≥ 263 (dB/m)    | 25%      |
|                       | Probe (M/XL)        | 62%/38%  |
| AST to platelet ratio index (APRI) | APRI | 0.35 (0.39)a, 0.025 (0.016 - 0.37)b |
|                       | APRI > 1.5          | 1.8%     |
| Fibrosis-4 (FIB-4) score | FIB-4 | 1.97 (1.33)a, 0.72 (1.07 - 2.37)b |
|                       | FIB-4 > 2.67        | 15%      |
| Non-alcoholic fatty liver disease fibrosis score (NFS) | NFS | -0.408 (1.61)a, -0.385 (-1.56 - 0.51)b |
|                       | NFS > 0.65          | 23%      |

^a Mean ± SD. ^b Median (IQR). LS: liver stiffness; CAP: controlled attenuated parameter; M/XL: medium/large size probe; SD: standard deviation.
Discussion

The results of our study demonstrate, based on TE, the magnitude of advanced fibrosis and steatosis among patients with ESRD. We show that advanced fibrosis and steatosis assessed by TE and CAP, respectively, were 21% and 25%. We also show that steatosis is common and associated with obesity and DM in this population. In those with ESRD, APRI and FIB-4 are not a reliable alternative to TE for these patients. Conversely, NFS did correlate with TE for identifying fibrosis, presumably from NASH given the high proportion with metabolic syndrome. In those with liver histology, TE correctly classified 71% of subjects for both fibrosis and steatosis. This finding is important considering the limited availability of TE for hepatic fibrosis evaluation.

Assessment of advanced fibrosis in ESRD is of utmost importance to gauge the risk of hepatic decompensation after renal transplantation in those with advanced fibrosis. In patients with ESRD and cirrhosis secondary to chronic liver disease, combined kidney-liver transplantation has better outcomes than kidney transplant alone [32]. Despite the increased diagnostic accuracy of non-invasive tests to detect hepatic fibrosis in general population, utility in ESRD is challenging with no studies to date on the subset of possible NAFLD patients undergoing renal transplant evaluation [33]. The major challenge is the reliance of most serum-based non-invasive tests on liver enzymes (AST and ALT) and clinical findings that may be nonspecific because of the underlying renal disease [11, 34]. Rising ALT levels have been directly associated with severity of hepatic fibrosis in patients with chronic HCV with and without ESRD [9, 35, 36]. We have previously demonstrated that diagnostic accuracy of non-invasive test is dependent on ALT levels in ESRD patients with chronic HCV infection [22]. These findings question the utility of non-invasive tests in ESRD that solely rely on laboratory values and anthropometric data for assessment of underlying hepatic fibrosis. In our cohort without HCV, the transaminases were normal likely secondary to underlying renal disease and therefore, APRI and FIB-4 scores were not able to assess advanced fibrosis despite detection by TE in a quarter of the patients. Thus, we cannot recommend using these serum-based tests in patients with NAFLD and ESRD being evaluated for renal transplant
who have normal ALT levels. However, since NFS includes BMI and DM, both associated with NASH, it is not surprising that it outperformed APRI and FIB-4 in this population. Subsequently, given the moderate performance of TE compared to histology in our subset, other non-invasive methods for fibrosis assessment such as MRE need to be studied in this population. Although studies have shown MRE to have higher diagnostic accuracy than TE in fibrosis assessment, the latter might impact the results. Because length of time on dialysis was not consistently reported, we were not able to assess its impact on fibrosis or steatosis. The impact of statins on steatosis among dialysis-dependent ESRD patients was not consistently reported, we were not able to assess its impact on fibrosis or steatosis. The impact of statins on steatosis was not assessed because the majority of the cohort had DL, the statins and doses were adjusted over time to control high cholesterol, and there is limited impact of statins on steatosis [45]. This study also occurred at a single institute with majority of population being African American men and as such the results may not be generalizable among different races or a female-predominant population. Though we excluded patients with active alcohol intake, those with remote history of alcohol use were not excluded. Though the overall cohort had non-invasive fibrosis assessment, the number of liver biopsies performed was small (n = 14), and therefore the true accuracy of each test, including TE could not be made. However, because

Table 5. Characteristics Including Clinical, Laboratory, Non-Invasive Tests and Histologic Findings of Subjects Undergoing Liver Biopsy

| Age (years) | Gender, M/F | Race, C/AA | BMI (kg/m²) | DM, Y/N | HTN, Y/N | DL, Y/N | ALT (U/L) | APRI | FIB-4 | NFS | TE (kPa) | CAP (dB/m) | AF (F3 - 4) | Steatosis (≥ 5%) |
|-------------|-------------|------------|-------------|---------|----------|---------|-----------|------|-------|-----|---------|------------|-------------|-----------------|
| 60          | F           | AA         | 16.3        | N       | Y        | N       | 178       | 2.38 | 5.35  | -1.549 | 7.3a     | 206a        | N°          | N°              |
| 67          | M           | AA         | 27.1        | N       | Y        | N       | 26        | 0.31a | 2.00a | -0.716 | 3.9a     | 302         | N°          | N°              |
| 63          | M           | AA         | 25.9        | N       | Y        | Y       | 41        | 0.42  | 2.09  | -1.026 | 21.6a    | 251a        | Y°          | N°              |
| 39          | M           | AA         | 26.1        | N       | Y        | N       | 14        | 0.15a | 0.76a | -2.219 | 5.9a     | 203         | N°          | N/A             |
| 65          | F           | C          | 32.3        | Y       | Y        | Y       | 9         | 0.140a| 1.50a | 0.342a | 17.1     | 245a        | N°          | N°              |
| 45          | M           | AA         | 26.4        | Y       | N        | N       | 9         | 0.26a | 1.92a | 1.708  | 14.4     | 178a        | N°          | N°              |
| 63          | M           | C          | 28.4        | N       | Y        | N       | 42        | 0.52a | 2.54a | -0.400 | 11.1     | 262         | N°          | Y°              |
| 56          | M           | C          | 24.4        | N       | Y        | Y       | 167       | 2.76  | 5.98  | -0.140 | 8.9a     | 223a        | N°          | N°              |
| 42          | M           | C          | 37.5        | Y       | Y        | N       | 15        | 0.16a | 0.86a | -0.448 | 16.2     | 340         | N°          | N°              |
| 66          | F           | C          | 21.6        | Y       | N        | Y       | 46        | 0.32  | 1.55  | -2.236 | 26.3a    | 100a        | Y°          | N°              |
| 54          | M           | C          | 23.9        | Y       | Y        | Y       |           |       |       |       | 26.3a    | 173a        | Y°          | N°              |
| 34          | F           | AA         | 29.7        | N       | Y        | N       | 86        | 0.55a | 1.00a | -1.946 | 6.6a     | 100a        | N°          | N°              |
| 51          | F           | C          | 28.3        | N       | Y        | N       | 20        | 0.37  | 2.11  | -0.477 | 23.9a    | 334a        | Y°          | N              |
| 60          | M           | AA         | 40          | Y       | N        | N       | 15        | 0.16  | 1.24  | 0.751  | 21.3a    | 248a        | Y°          | N°              |

*Representing those with concordant APRI, FIB-4, NFS, or TE with histology for advanced fibrosis (AF) and steatosis. M: male; F: female; C: Caucasian; AA: African American; Y: yes; N: no; DM: diabetes mellitus; HTN: hypertension; DL: dyslipidemia; ALT: alanine aminotransferase; APRI: AST to platelet ratio index; FIB-4: Fibrosis-4; NFS: non-alcoholic fatty liver disease fibrosis score; TE: transient elastography; CAP: controlled attenuated parameter; AF: advanced fibrosis; N/A: not available.
liver biopsy would not be performed in all those with ESRD, especially those with normal ALT, this question may never be answered. A 12-week window was selected between these tests to reduce clinical status change that would influence non-invasive hepatic fibrosis assessment. We have to acknowledge that most institutes including ours have adopted non-invasive assessment of fibrosis in patients undergoing renal transplant evaluation as liver biopsy is an invasive modality with limitations [16-19]. However, there are only limited data on the diagnostic accuracy of non-invasive tests in ESRD, and it has not been addressed in patients undergoing renal transplant evaluation. Therefore, our results are important and novel as it addresses the utility of non-invasive assessment of hepatic fibrosis in ESRD patients without viral hepatitis undergoing renal transplant evaluation. Fibrosis assessment is important in these patients as in addition to gauging the risk of hepatic decompensation post kidney transplant it also aids in identifying potential patients for combined liver-kidney transplantation. While features of the metabolic syndrome were common in our cohort, the cross-sectional nature of our analysis could not address if ESRD contributed to NAFLD or if NAFLD contributed to ESRD. Although almost one-quarter of our cohort had steatosis, it is unclear if steatosis itself, independent of fibrosis, impacts post-renal transplant survival.

In conclusion, in ESRD patients, our data suggest that advanced fibrosis (LS ≥ 9 kPa) and steatosis (CAP ≥ 263 dB/m) by TE were common (21-25%) despite normal liver enzymes. This was not detected by APRI or FIB-4 though fibrosis could be detected by NFS. When compared to liver histology in a smaller group, TE had moderate ability to predict advanced fibrosis in these patients. NFS, but not APRI or FIB-4, was also associated with advanced fibrosis confirmed by liver biopsy. Therefore, we recommend that TE and NFS be used to identify ESRD patients that are at low risk for advanced fibrosis. Since liver biopsy is rarely done in ESRD patients with normal ALT levels and TE and NFS are suboptimal, future studies using MRE for both fibrosis and steatosis assessment with histology as the gold standard are needed to better identify patients with advanced liver disease especially in those undergoing renal transplant evaluation.

Supplementary Material

Suppl 1. Formulas for selected non-invasive tests.

Acknowledgments

None to declare.

Financial Disclosure

Syed Taseen, Chadha Nikita, Kumar Dhiren, and Gupta Gaurav have no disclosures. Sterling Richard K: research support (Gilead, Abbvie, Abbott, Roche Diagnostics), DSMB (Pfizer, AskBio).

Conflict of Interest

None to declare.

Informed Consent

Patients were not required to give informed consent to the study because the analysis used anonymous data.

Author Contributions

Syed Taseen: study design, data retrieval, manuscript drafting, revisions and approval of submitted version of the manuscript. Chadha Nikita: data retrieval, manuscript drafting and approval of submitted version of the manuscript. Kumar Dhiren and Gupta Gaurav: critical appraisal and revision of the final manuscript. Sterling Richard K: principal investigator, who conceived, supervised, reviewed, and approved the final manuscript.

Data Availability

Any inquiries regarding supporting data availability of this study should be directed to the corresponding author.

Abbreviations

ESRD: end-stage renal disease; NAFLD: non-alcoholic fatty liver disease; TE: transient elastography; CAP: controlled attenuation parameter; LS: liver stiffness; NFS: NAFLD fibrosis score; APRI: AST to platelet ratio index; AF: advanced fibrosis; NIT: non-invasive test; DM: diabetes mellitus; HTN: hypertension; DL: dyslipidemia; MRE: magnetic resonance elastography; CKD: chronic kidney disease; SD: standard deviation; IQR: interquartile range; SN: sensitivity; SP: specificity; PPV: positive predictive value; NPV: negative predictive value; BMI: body mass index; HCV: hepatitis C

References

1. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11-20.
2. Arshad T, Golabi P, Henry L, Younossi ZM. Epidemiology of non-alcoholic fatty liver disease in North America. Curr Pharm Des. 2020;26(10):993-997.
3. Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, Ahmed A. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148(3):547-555.
4. Musso G, Cassader M, Cohney S, Pinach S, Saba F, Gambino R. Emerging liver-kidney interactions in nonalcoholic fatty liver disease. Trends Mol Med. 2015;21(10):645-662.

5. Mikolasevic I, Racić S, Bubic I, Jelic I, Stimač D, Orlic L. Chronic kidney disease and nonalcoholic fatty liver disease proven by transient elastography. Kidney Blood Press Res. 2013;37(4-5):305-310.

6. Targher G, Chonchol M, Zoppini G, Abaterusso C, Bonera E. Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: is there a link? J Hepatol. 2011;54(5):1020-1029.

7. Musso G, Gambino R, Tabibian JH, Ekstedt M, Kecharias S, Hamaguchi M, Hultrancz R, et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med. 2014;11(7):e1001680.

8. Marcuscelli M, Chonchol M. NAFLD and Chronic Kidney Disease. Int J Mol Sci. 2016;17(4):562.

9. Samson SL, Garber AJ. Metabolic syndrome. Endocrinol Metab Clin North Am. 2014;43(1):1-23.

10. Cheng BC, Yen YH, Chen JF, Wu CK, Chang KC, Tseng PL, Tsai MC, et al. Transient elastography as a screening tool for liver fibrosis in a large hemodialysis population. Sci Rep. 2017;7:46458.

11. Sterling RK, Sanyal AJ, Luketic VA, Stratvig RT, King AL, Post AB, Mills AS, et al. Chronic hepatitis C infection in patients with end stage renal disease: characterization of liver histology and viral load in patients awaiting renal transplantation. Am J Gastroenterol. 1999;94(12):3576-3582.

12. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. American Association for the Study of Liver Diseases. Liver biopsy. Hepatology. 2009;49(3):1017-1044.

13. Cotler SJ, Diaz G, Gundlapalli S, Jakate S, Chawla A, Mital D, Jensik S, et al. Characteristics of hepatitis C in renal transplant candidates. J Clin Gastroenterol. 2002;35(2):191-195.

14. Hoodeshenas S, Yin M, Venkatesh SK. Magnetic resonance elastography of liver: current update. Top Magn Reson Imaging. 2018;27(5):319-333.

15. Mikolasevic I, Orlic L, Franjic N, Hauser G, Stimac D, Milic S. Transient elastography (FibroScan((R))) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand? World J Gastroenterol. 2016;22(32):7261-7265.

16. Perazzo H, Fernandes FF, Gomes A, Terra C, Perez RM, Figueiredo FA. Interobserver variability in transient elastography analysis of patients with chronic hepatitis C. Liver Int. 2015;35(5):1533-1539.

17. Selber-Sagi S, Yeshua H, Shlomai A, Blendis L, Leshno M, Levi T, Halpern Z, et al. Sampling variability of transient elastography according to probe location. Eur J Gastroenterol Hepatol. 2011;23(6):507-514.

18. Khunpakdee N, Jayanama K, Kaewdoung P, Promson K, Rattanpaisiri S, Warodomwichit D, Kantachuesiri S, et al. Transient elastography in end-stage renal disease patients on hemodialysis: the effect of net fluid withdrawal. Blood Purif. 2015;40(3):256-259.

19. Taneja S, Borkakoty A, Rathi S, Kumar V, Duseja A, Hiranman RK, Gupta KL, et al. Assessment of liver fibrosis by transient elastography should be done after hemodialysis in end stage renal disease patients with liver disease. Dig Dis Sci. 2017;62(11):3186-3192.

20. Kellner P, Anadol E, Huneburg R, Hundt F, Bos D, Klein B, Woitas RP, et al. The effect of hemodialysis on liver stiffness measurement: a single-center series. Eur J Gastroenterol Hepatol. 2013;25(3):368-372.

21. Ray L, Nanda SK, Chatterjee A, Sarangi R, Ganguly S. A comparative study of serum aminotransferases in chronic kidney disease with and without end-stage renal disease: Need for new reference ranges. Int J Appl Basic Med Res. 2015;5(1):31-35.

22. Schmoyer CJ, Kumar D, Gupta A, Sterling RK. Diagnostic accuracy of noninvasive tests to detect advanced hepatic fibrosis in patients with hepatitis C and end-stage renal disease. Clin Gastroenterol Hepatol. 2020;18(10):2332-2339.e2331.

23. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marroja JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518-526.

24. Sterling RK, Lissen E, Clumreck N, Sola R, Correa MC, Montaner J, M SS, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317-1325.

25. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846-854.

26. Sandrin L, Fourquet B, Hasquesnoph JM, Yon S, Fournier C, Mal F, Christidis C, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003;29(12):1705-1713.

27. Siddiqui MS, Vuppallanchi R, Van Natta ML, Hallinan E, Kowdley KV, Abdelmalek M, Neuschwander-Tetri BA, et al. Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2019;17(1):156-163.e152.

28. Desmet VJ, Knoedler RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis [Hepatology 1981;1:431-435]. J Hepatol. 2003;38(4):382-386.

29. Loaeza-del-Castillo A, Paz-Pineda F, Oviedo-Cardenas E, Sanchez-Avila F, Vargas-Vorackova F. AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis. Ann Hepatology. 2008;7(4):350-357.

30. Vallet-Pichard A, Mallet V, Pol S. FIB-4: a simple, inexpensive and accurate marker of fibrosis in HCV-infected patients. Hepatology. 2000;34(3):769; author reply 769-770.
31. Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ, Nash Clinical Research N. Comparison of noninvasive markers of fibrosis in patients with non-alcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7(10):1104-1112.
32. Dube GK, Cohen DJ. Simultaneous liver and kidney transplantation. Curr Opin Nephrol Hypertens. 2007;16(6):547-553.
33. Lurie Y, Webb M, Cyttner-Kuint R, Shteingart S, Lederkremer GZ. Non-invasive diagnosis of liver fibrosis and cirrhosis. World J Gastroenterol. 2015;21(41):11567-11583.
34. Tatar B, Kose S, Pala E, Tatar E. Inflammatory biomarkers and liver histopathology in non-uremic and uremic chronic hepatitis C patients. Acta Medica (Hradec Kralove). 2017;60(2):71-75.
35. Shiffman ML, Stewart CA, Hofmann CM, Contos MJ, Luketic VA, Sterling RK, Sanyal AJ. Chronic infection with hepatitis C virus in patients with elevated or persistently normal serum alanine aminotransferase levels: comparison of hepatic histology and response to interferon therapy. J Infect Dis. 2000;182(6):1595-1601.
36. Perez RM, Ferreira AS, Medina-Pestana JO, Lanzoni VP, Silva AE, Ferraz ML. Is alanine aminotransferase a good marker of histologic hepatic damage in renal transplant patients with hepatitis C virus infection? Clin Transplant. 2005;19(5):622-625.
37. Park CC, Nguyen P, Hernandez C, Bettencourt R, Ramirez K, Fortney L, Hooker J, et al. Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. Gastroenterology. 2017;152(3):598-607 e592.
38. Hsu C, Caussy C, Imao K, Chen J, Singh S, Kaulback K, Le MD, et al. Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants. Clin Gastroenterol Hepatol. 2019;17(4):630-637 e638.
39. Mikolasevic I, Racki S, Lukenda V, Milic S, Pavletic-Persic M, Orlic L. Nonalcoholic Fatty liver disease in renal transplant recipients proven by transient elastography. Transplant Proc. 2014;46(5):1347-1352.
40. Alric L, Kamar N, Bonnet D, Danjoux M, Abravanel F, Lauwers-Cances V, Rostaing L. Comparison of liver stiffness, fibrotest and liver biopsy for assessment of liver fibrosis in kidney-transplant patients with chronic viral hepatitis. Transpl Int. 2009;22(5):568-573.
41. Shen Y, Wu SD, Wu L, Wang SQ, Chen Y, Liu LL, Li J, et al. The prognostic role of liver stiffness in patients with chronic liver disease: a systematic review and dose-response meta-analysis. Hepatol Int. 2019;13(5):560-572.
42. Liu CH, Liang CC, Huang KW, Liu CJ, Chen SI, Lin JW, Hung PH, et al. Transient elastography to assess hepatic fibrosis in hemodialysis chronic hepatitis C patients. Clin J Am Soc Nephrol. 2011;6(5):1057-1065.
43. Sasso M, Beaugrand M, de Ledinghen V, Douvin C, Marcelin P, Poupon R, Sandrin L, et al. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010;36(11):1825-1835.
44. Karlas T, Petroff D, Sasso M, Fan JG, Mi YQ, de Ledinghen V, Kumar M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66(5):1022-1030.
45. Eslami L, Merat S, Malekzadeh R, Nasseri-Moghaddam S, Aramini H. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Cochrane Database Syst Rev. 2013;12:CD008623.